News Sentiment

NAMS sentiment intelligence

NewAmsterdam Pharma Company N.V. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.68 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.2% over one week, +6.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -10.2% Price reacting lower
Trend fit Trend inactive 6.2% over four weeks
Fair value 40.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 16
Market source 15
Stock Titan 4
simplywall.st 4
Finviz 2
GlobeNewswire 2
MT Newswires 2
Bitget 1

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 24
Regulatory and legal 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-54 of 54
TradingView Direct company coverage

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC

This article provides financial data for NewAmsterdam Pharma Company N.V. (LSX: A3DUAC), specifically focusing on its enterprise value to revenue forward. The content is primarily a data placeholder from TradingView, offering a snapshot of the company's financial overview without

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:10
Source
TradingView
TradingView Direct company coverage

NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC)

This article provides actuals and estimates for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC), detailing financial data, analyst forecasts, and various stock performance metrics. It covers information on the company's stock price, market capitalization, earnings, revenue, and fut

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS

This article provides the "Price to earnings forward" value for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS). It specifies that the market is currently closed and no trades have occurred. The content appears to be a stub or a section of a larger financial data display from Tra

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 03:40
Source
TradingView